"Emerging wet AMD therapies including Fovista and abicipar pegol (Allergan/Molecular Partners) will need to be priced competitively to Eylea and Lucentis in order to garner favorable tier placement.
Just a quick not that HROW made another needle moving acquisition, terms not disclosed. BYOOVIZ is a biosimilar for Lucentis, and OPUVIZ is a biosimilar for Eylea. Lucentis and Eylea revenue in 2024 ...
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1 Agreement builds on the proven and successful collaboration of ...
Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...
We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Harrow, Inc. is one of them. Harrow, Inc. (NASDAQ:HROW), a leading U.S.-based pharmaceutical company, is ...
More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
Teva Pharmaceuticals has announced a strategic collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, a biosimilar candidate to Eylea® (aflibercept), in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results